Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 0.56 |
| ▸ | MAOB | P27338 | 13/20 | 0.56 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LSS | P48449 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300476 | 0.92 | XDH (0.61) | MAOAMAOBXDHKDM4ENPC1 | |
| SCHEMBL21084279 | 0.88 | MAOB (0.53) | MAOAMAOBXDHKDM4ENPC1 | |
| SCHEMBL20124806 | 0.87 | MAOA (0.55) | MAOAMAOBXDHKDM4ENPC1 | |
| SCHEMBL4207969 | 0.86 | MAPT (0.59) | MAOAMAOBXDHKDM4ENPC1 | |
| SCHEMBL1796580 | 0.86 | XDH (0.57) | MAOAMAOBXDHKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL4213278 | 0.85 | MAPT (0.58) | MAOAMAOBXDHKDM4ENPC1 | |
| SCHEMBL13579134 | 0.85 | MAOA (0.51) | MAOAMAOBXDHKDM4ENPC1 | |
| SCHEMBL12795345 | 0.84 | MAOA (0.55) | MAOAMAOBKDM4ENPC1ALDH1A1 | |
| SCHEMBL12795166 | 0.84 | MAOA (0.50) | MAOAMAOBXDHKDM4ENPC1 | |
| SCHEMBL12795334 | 0.84 | MAOA (0.50) | MAOAMAOBXDHKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389769-B2 | Polymerizable type II photoinitiators and curable compositions | AGFA GRAPHICS NV (BE) | 2013-03-05 | — | — | US | disclosed |
| US-8389769-B2 | Polymerizable type II photoinitiators and curable compositions | AGFA GRAPHICS NV (BE) | 2013-03-05 | — | — | US | disclosed |
| US-20110063388-A1 | POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2011-03-17 | — | — | US | disclosed |
| US-20110063388-A1 | POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | AGFA GRAPHICS NV (BE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110063388-A1 | POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS | CCNH, CRKL, ERH | MAOA 2208/4885MAOB 2396/4885XDH 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.